1. DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn's disease: Pharmacokinetic findings from VISIBLE 2. (15th January 2020) Authors: Chen, C; Rosario, M; Polhamus, D; Dirks, N; Zhang, W; Sun, W; Kisfalvi, K; Feagan, B; Sandborn, W; Vermeire, S; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S056 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P490 A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis. (25th January 2019) Authors: Rosario, M; Polhamus, D; Chen, C; Sun, W; Dirks, N Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S357 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P529 Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1. (25th January 2019) Authors: Rosario, M; Polhamus, D; Dirks, N; Lock, R; Yao, X; Chen, J; Chen, C; Sun, W; Feagan, B; Sandborn, W; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗